
    
      Detailed Description:

      In this study, eligible subject will be randomized into study arm or control arm to accept
      study treatment. Paticipant was confirmed without EGFR activating mutation or ALK fusion and
      received no prior systemic therapy. Patients would receive Camrelizumab/placebo in
      combination with chemotherapy for 4-6 cyclesï¼Œnon-squamous subject followed by
      Camrelizumab/placebo + pemetrexed as maintenance treatment until progression or unacceptable
      toxicity, squamous subject followed by Camrelizumab/placebo as maintenance treatment until
      progression or unacceptable toxicity, Camrelizumab/placebo for a maximum of 2 years.
    
  